+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating pembrolizumab, an immunotherapy, in children and teens with advanced melanoma, solid tumors, and lymphomas that are advanced, relapsed, or refractory. The study aims to determine if different doses of pembrolizumab can reduce or eliminate these cancers. Enrollment restrictions have been applied over time for certain age groups and tumor types. Participants receive pembrolizumab intravenously at a starting dose of 2 mgkg up to 200 mg every three weeks. Different groups include children with melanoma, solid tumors, relapsed refractory classical Hodgkin lymphoma, MSI-H solid tumors, TMB-H solid tumors, and high-risk resected melanoma. Enrollment for some groups has been closed with protocol amendments. Participants will be monitored for tumor response using established cancer criteria over up to two years. Researchers will assess objective response rates, duration of response, progression-free survival, adverse events, and drug tolerability. Safety and disease status are tracked during and after treatment, with study participation lasting until February 2028.

Age: 6Months - 17YearsAll GendersPhase 1Phase 2
16 locations